Theriva Biologics Completes $7.5 Million Public Offering

An update from Theriva Biologics ( (TOVX) ) is now available.

On May 8, 2025, Theriva Biologics completed a public offering, raising approximately $7.5 million through the sale of common stock and warrants. The proceeds are intended for working capital, research and development, and potential acquisitions. The offering, facilitated by A.G.P./Alliance Global Partners, includes restrictions on future stock transactions to stabilize market conditions. This strategic move aims to bolster Theriva’s operational capabilities and market positioning in the biopharmaceutical industry.

Spark’s Take on TOVX Stock

According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.

Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.

To see Spark’s full report on TOVX stock, click here.

More about Theriva Biologics

Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, particularly in areas with high unmet medical needs. The company is advancing a new oncolytic adenovirus platform for intravenous, intravitreal, and antitumoral delivery to enhance tumor cell death and improve the efficacy of co-administered cancer therapies. Its lead candidates include VCN-01, SYN-004, and SYN-020, targeting various cancer and gastrointestinal conditions.

Average Trading Volume: 785,044

Technical Sentiment Signal: Sell

Current Market Cap: $3.78M

See more data about TOVX stock on TipRanks’ Stock Analysis page.